Female sex hormone receptor status in advanced hepatocellular carcinoma and outcome after surgical resection

Surgery

Volumn 121, Issue 4, 1997, Pages 456-461

  Jonas, Sven ^a,b   Bechstein, Wolf O ^a   Heinze, Thomas ^a   Kling, Norbert ^a   Lobeck, Hartmut ^a   Tullius, Stefan G ^a   Steinmueller, Thomas ^a   Neuhaus, Peter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0030974892     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(97)90317-2     Document Type: Article

References (30)

1. Farmer DG, Rosove MH, Shaked A, Busuttil RW. Current treatment modalities for hepatocellular carcinoma. Ann Surg 1994; 219:236-47.
2. Pichlmayr R, Ringe B, Bechstein WO, et al. Approach to primary liver cancer. Recent Results Cancer Res 1988;110:65-73.
3. Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 1980; 46:372-9.
4. Nagao T, Goto S, Kawano N, et al. Hepatic resection for hepato-cellular carcinoma: clinical features and long-term prognosis. Ann Surg 1987;205:33-40.
5. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-51.
6. Bechstein WO, Blumhardt G, Lobeck H, Keck H, Lemmens HP, Knoop M, et al. Selection of small hepatocellular carcinoma improves long-term results of hepatic transplantation for malignancy. Transpl Int 1994;7(suppl 1):S238-40.
7. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resections versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214:221-9.
8. Rizzi PM, Kane PA, Ryder SD, et al. Accuracy of radiology in detection of hepatocellular carcinoma before liver transplantation. Gastroenterology 1994;107:1425-9.
9. Carr BI. A controlled prospective randomized trial comparing intra-arterial (I/A) cisplatinum, doxorubicine and S/Q interferon alpha, with or without lipiodol for hepatocellular carcinoma (HCC). Hepatology 1992;16:60.
10. Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995;21:1535-42.
11. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980;46:2884-8.
12. Bezwoda WR, Esser JD, Dansey R, Kessel I, Lange M. The value of estrogen and progesterone receptor determination in advanced breast cancer: estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer 1991;68:867-72.
13. Boix L, Bruix J, Castells A, et al. Sex hormone receptors in hepatocellular carcinoma: Is there a rationale for hormonal treatment? J Hepatol 1993;17:187-91.
14. Nagasue N, Ito A, Yukaya H, Ogawa Y. Estrogen receptors in hepatocellular carcinoma. Cancer 1986;57:87-91.
15. Nagasue N, Kohno H, Yamanoi A, Kimoto T, Ghang YC, Nakamura T. Progesterone receptor in hepatocellular carcinoma. Cancer 1991;67:2501-5.
16. Nagasue N, Kohno H, Chang YC, Yamanoi A, Nakamura T, Yukaya H, et al. Clinicopathologic comparisons between estrogen receptor-positive and -negative hepatocellular carcinomas. Ann Surg 1990;212:150-4.
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with folin-phenol reagent. J Biol Chem 1951:193:265-75.
18. Goussard J, Lechevrel C, Martin PM, Roussel G. Comparison of monoclonal antibodies and tritiated ligands for estrogen receptors assays in 241 breast cancer cytosols. Cancer Res 1986; 46(suppl):4282s-7s.
19. Thorpe SM. Monoclonal antibody technique for detection of estrogen receptors in human breast cancer: greater sensitivity and more accurate classification of receptor status than the dextrancoated charcoal method. Cancer Res 1987;47:6572-5.
20. Okuda K, Fujimoto I, Hannai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987;47:4967-72.
21. Farinati F, Salvagnini M, de Maria N, Fornasiero A, Chiaramonte M, Rossaro L, et al. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol 1990;11: 297-301.
22. Cerezo FJM, Tomas A, Donoso L, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994;20:702-6.
23. Gagliardi A, Collins DC. Inhibition of angiogenesis by antiestrogens. Cancer Res 1993;53:533-5.
24. Huynh HT, Tetenes E, Wallace L, Pollak M. In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res 1993:53:1727-30.
25. Nogushi S, Motomura K, Inaji H, Imaoka S, Koyama H. Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer. Cancer 1993;72:131-6.
26. Francavilla A, DiLeo A, Eagon PK, et al. Regenerating rat liver: correlation between estrogen receptor localization and deoxyribonucleic acid synthesis. Gastroenterology 1984:86:562-7.
27. Eagon PK, Porter LE, Francavilla A, et al. Estrogen and androgen receptors in liver: their role in liver disease and regeneration. Semin Liver Dis 1985;5:59-69.
28. Francavilla A, Eagon PK, DiLeo A, et al. Sex hormone related functions in regenerating male rat liver. Gastroenterology 1986; 91:1263-70.
29. Winneker RC, Clark JH. Estrogenic stimulation of the antiestrogen specific binding site in rat uterus and liver. Endocrinology 1983;112:1910-5.
30. Francavilla A, Polimeno L, DiLeo A, et al. The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology 1989;9:614-20.